Rasa has launched two coffee alternative mixes with adaptogenic herbs and mushrooms instead of caffeine, the Classic Rasa and Café Rasa.
Rasa CEO and founder, Lopa van der Mersch, said Classic Rasa, which is made of roasted chicory, burdock root, and date seed to create a dark, rich, and sweet blend, is the most coffee-like alternative out there.
It also has adaptogens: red Asian ginseng, cordyceps, rhodiola, gynostemma, shatavari, and maca.
Meanwhile, Café Rasa blends freeze-fried coffee from Chiapas, Mexico, with adaptogens that are said to soften coffee’s downsides whilst supplementing caffeine’s fatigue-fighting abilities.
According to van der Mersch, the two new mixes open new channels of distribution and provide everyone with the opportunity to drink Rasa.
Co-founder, Ben LeVine, added that their process includes brewing the herbs over several hours like a standard decoction, then drying it and granulating it to produce a supremely delicious, dissolvable, and bioavailable mix.


Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions
South Korea Extends Bond Market Stabilization Measures Amid Rising Financial Risks
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Asian Technology and Chipmaking Stocks Slide as AI Spending Concerns Shake Markets
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute
Ireland Limits Planned Trade Ban on Israeli Settlements to Goods Only 



